Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction

International Heart Journal

Volumn 47, Issue 5, 2006, Pages 715-725

  Suzuki, Hiroshi ^a   Kusuyama, Taro ^a   Omori, Yasutoshi ^a   Soda, Teruko ^a   Tsunoda, Fumiyoshi ^a   Sato, Takatoshi ^a   Shoji, Makoto ^a   Iso, Yoshitaka ^a   Kondo, Takeshi ^a   Koba, Shinji ^a   Geshi, Eiichi ^a   Katagiri, Takashi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Myocardial remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; ENALAPRIL; FEMALE; HUMANS; INDOLES; LISINOPRIL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TETRAZOLES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33751089291     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.715     Document Type: Article

References (23)

1. Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infraction. experimental observations and clinical implications. Circulation 1990; 81: 1161-72. (Review)
2. St John Sutton M, Pfeffer MA, Plappert T, et al, Quantitative two-dimensional echocardiogaphic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 1994; 89:68-75.
3. Jirmar R, Pelouch V, Widimsky P, et al. Influence of primary coronary intervention on myocardial collagen metabolism and left ventricular remodeling predicted by collagen metabolism markers. Int Heart J 2005; 46: 949-59.
4. ACE Inhibitor Myocardial Infarction collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infraction: systematic overview of individual data from 100,000 patients in randomized trails. Circulation 1998; 97: 2202-12.
5. Bonarjee VV, Carstensen S, Caidahl & Nilsen DW, Edner M, Berning J. Attenuation of left ventricular dilatation after acute myocardial infraction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. Am J Cardiol 1993; 72: 1004-9.
6. Tan WH, Vagelos RH, Yee Y, et al. Neurohumoral and clinical responses to high versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70-8.
7. Wolny A., Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circ Res 1997; 80: 219-27.
8. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613-21. (Review)
9. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee, of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trail. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-60.
10. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
11. Riegger GA, Bouzo H, Petr P, et al. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224-30.
12. Dodge HT, Sandler H, Ballew DW, et al. The use of biplane angiography for the measurement of left ventricular volume in man. Am Heart J 1960; 60: 762-76.
13. Meredith P. Achieving quality 24-h blood pressure control with candesartan cilexetil. Blood Pressure 2000; 1: 23-6. (Review)
14. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42:905-10.
15. Wassmann S, Hilgers S, Laufs U. Bohm M, Nickening G Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1208-12.
16. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-5.
17. Matsumori A; Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003; 5: 669-77.
18. Pfeffer MA, Swedberg K, Granger CB, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
19. Kondo J, Sone T, Tsuboi H, et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J 2003; 146: E20.
20. Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003; 26: 453-8.
21. Kusuoka H, Koretsune Y, Chino M, et al; for the CAMPAIGN investigators. Disparity in the process and outcome of the treatment for acute myocardial infarction in Japan: CAMPAIGN Study in the National Hospital Network. Circulation J 2005; 69: 1447-53.
22. Pristipino C, Beltrame JF, Finocchiaro ML, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 2000; 101: 1102-8.
23. Japanese β-blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infraction in Japanese subjects. Am J Cardiol 2004; 93: 969-73.